Grants Search Results

People between the ages of 15 to 40 years old with cancer have a lot of challenges like having to juggle their cancer diagnoses with their day to day lives - school, a job or family, and even things like going out with friends or keeping up with exercise or hobbies. They can feel isolated, afraid and unaware of new drugs that can help, or could be far away from hospitals that offers treatment through clinical trials. This grant supports an adolescent and young adult patient navigator to help young people address these issues throughout their treatment, get them the help they need and steer them towards newer treatments through trials that may increase their chance of a cure from cancer.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The Jim Brady's St. Baldrick's grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. This grant is named in honor of the 20th annual head-shaving event at Jim Brady's and to celebrate its many volunteers over the years who have supported the event at the birthplace of St. Baldrick's.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a nurse navigator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Adolescent and Young Adult (AYA) patients with cancer form a unique group, different than both little children and older adults with cancer. Historically the AYA cancer population has delayed access to care, delay in diagnosis, inconsistent treatment and follow-up, and decreased participation in clinical trials, often leading to inferior survival and quality of life compared to either younger children or older adults. Stony Brook Cancer Center recently started a formal AYA cancer program, with the goal of providing enhanced care and research for AYA patients. This grant supports a nurse navigator for the AYA program, to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Adolescent and young adults with cancer (AYAs) represent a unique group of patients that do not do as well on treatment when compared to younger children and older adults. There are many reasons why AYAs do not do as well, which include the specific types of cancers that affect this age group, poor participation in clinical trials, psychosocial challenges of being a teenager with a cancer diagnosis, and the location of cancer treatment. This grant supports the development of an AYA program that will help meet the specific needs of this patient population, with a focus on increased access to clinical trials, to improve overall outcomes.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports an Adolescent and Young Adult (AYA) Clinical Research Nurse to ensure that more AYAs can be treated on clinical trials, often their best hope for a cure.

Fortunately, the majority of children with cancer can be cured of their disease. For those children that are not cured, new therapies and new approaches are needed. Additionally, for those children who are cured, we need to work on decreasing the risk of long-term side effects by understanding how chemotherapy medications are metabolized in each individual patient and developing more targeted therapies to decrease off-target side effects. Children's Hospital & Research Center Oakland is currently in process of developing a tumor/tissue bank in order to have patient samples available for collaborative researchers to help tackle some of these questions in order to improve the outcomes and side effects for children with cancer. Some of the research collaborators who are currently utilizing samples from the tumor bank are looking at new methods to harness the immune system to help with killing cancer cells which can minimize some of the side effects from chemotherapy. Additionally they are using samples from the tumor bank to look at the genetics of each person's particular cancer to help identify potential therapeutic targets. Researchers can also utilize this genetic information to answer other genetic questions such as why certain patients metabolism certain chemotherapy medications so differently than other patients and ultimately why certain drugs appear more effective in certain patients than others. This grant supports a Clinical Research Associate to support the tumor/tissue bank.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded two projects. Project 1: The early bone marrow relapse in Acute lymphoblastic Leukemia has a low remission rate. Previous case studies showed that adding a new agent, Bortezomib, on top of the Rituximab, together with intensive chemotherapy, may achieve remission for adults. The study aims to add this new agent Bortezomib to paediatric treatment to improve survival rate. Project 2: Previous studies showed that MRD monitoring of Acute Lymphoblastic Leukemia is a very important tool to guide the stratification of treatment. This study introduces a new penal of antibodies to improve accuracy and sensitivity for MRD monitoring and aims at developing a more cost-effective approach of MRD monitoring in Hong Kong.

Pediatric cancer research remains limited by a lack of data sharing. While clinical trials remain the cornerstone of pediatric cancer breakthroughs, a consistent and reliable way to store and share data from these trials is lacking. The University of Chicago Pediatric Cancer Data Commons was established to solve this important problem. Sitting alongside the NCI's Genomic Data Commons, the PCDC serves as a neutral repository for data from clinical trials. This information is first converted into a commons format that is consistent across pediatric cancers. The PCDC allows researchers to search over thousands of patients' data to see quickly what data are available for study. Researchers can then apply for access to data, and the PCDC streamlines the process of requesting and downloading data. Finally, the PCDC connects researchers to other kinds of data, including genomic information so critical to studying pediatric cancer. This grant supports personnel to help build the PCDC, so that researchers can efficiently access data and create new ways to study pediatric cancer.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.